Researchers at the National Cancer Institute (NCI) RNA Biology Laboratory have developed nanoparticles that can deliver an agent (i.e., therapeutic or imaging) and release the agent upon targeted photoactivation allowing for controlled temporal and localized release of the agent.
Surgery specialists from Johns Hopkins University, in collaboration with researchers at the National Cancer Institute (NCI), developed peptide hydrogel compositions and methods to suture blood vessels during microsurgery. The hydrogels particularly benefit surgeons in whole tissue transplant procedures. The NCI seeks co-development research collaborations for further development of this technology.
Researchers at the National Cancer Institute (NCI) have developed a bioluminescent MB49-luciferase bladder cancer cell line that can be used in preclinical studies to evaluate anti-cancer agents in bladder cancer. NCI seeks parties to non-exclusively license this research material.
The National Cancer Institute (NCI) seeks parties interested in licensing a human synovial sarcoma cell line (A2243). This cell line is an excellent research tool to study synovial sarcoma with a focus on chromosome translocations.
The National Institutes of Health, through The National Institutes of Health - Clinical Center (NIH-CC) and the National Heart Lung and Blood Institute (NHLBI), seeks licensing and/or co-development partners for a nitric oxide cream for the treatment of ulcers associated with sickle cell disease.
Researchers at the National Institutes of Health Clinical Center (NIHCC) and Northern Arizona University (NAU) seek licensing and/or co-development research collaborations for a wearable, pediatric, robotic exoskeleton that facilitates knee extension during walking to provide motorized movement assistance and training through the gait cycle. The Robotic Exoskeleton is specifically designed for therapy of crouch gait in children with cerebral palsy (CP). The design is a customizable human-machine interface that allows an individualized assistance protocol to help preserve and enhance muscle strength and control. Early clinical results from this intervention appear promising for a condition having few effective long-term interventions.
Researchers at the National Eye Institute (NEI), have developed a cryopreservation and cell recovery system designed specifically for the efficient cryopreservation, transportation and subsequent thawing of monolayers and tissues on a substrate. This closed cryopreservation/defrost system allows for sterility in addition to increased viability, recovery and safety of tissues that can be used for in vitro culture or surgical transplantation.
The National Institutes of Health - Clinical Center (NIH-CC) seeks to license and/or co-develop methods of reading chest x-rays using a deep learning models to detect a disease and describe its contents.
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research and development partners or licensees for novel composite hydrogels that can be used in tissue repair and other applications. Single gel networks used in tissue engineering and tissue repair applications generally become softer and more flaccid as they swell. The gels described in this technology, however, which comprise a swellable crosslinked polymer hydrogel dispersed in a crosslinked polymer matrix, mimic critical material properties of tissue extracellular matrix (ECM), for instance, becoming stiffer and tougher upon swelling.
The National Cancer Institute (NCI) seeks licensing partners for a novel modified insect cell line, Sf9-ET, that can quickly and efficiently determine baculovirus titers during the expression of recombinant proteins from a baculovirus-based protein expression system.
In collaboration with the National Cancer Institute (NCI), researchers at The Eunice Kennedy Shriver National Institute on Child Health and Human Development (NICHD) have discovered monoclonal antibodies that bind to matrilin-3, a protein specifically expressed in cartilage tissue, that could be used for treating or inhibiting growth plate disorders, such as a skeletal dysplasia or short stature. The monoclonal antibodies can also be used to target therapeutic agents, such as those for anti-arthritis, to cartilage tissue. NICHD seeks statements of capability or interest from parties interested in collaborative research to co-develop, evaluate, and/or commercialize treatment of skeletal disorders using targeting antibodies.